September 7, 2017 / 11:56 AM / 15 days ago

BRIEF-Celgene provides update on the Fusion clinical program

Sept 7 (Reuters) - Celgene Corp

* Celgene provides update on the Fusion clinical program

* ‍Patients enrolled in trials on partial clinical hold who are receiving clinical benefit from treatment as determined by investigator,may remain on treatment​

* ‍U.S. FDA has placed a partial clinical hold on five trials and a full clinical hold on one trial in celgene fusion program​

* ‍FDA has placed a partial clinical hold on five trials and a full clinical hold on one trial in celgene Fusion program​

* ‍Patients enrolled in trial on full clinical hold will be discontinued from treatment​

* FDA decision based on risks identified in trials for pembrolizumab in patients with multiple myeloma in combination with immunomodulatory agents​

* ‍Clinical holds allow for additional information to be collected to further understand risk benefit profile of program​

* ‍No new patients will be enrolled into trials placed on hold​

* ‍Trial placed on full clinical hold is MEDI4736-MM-002​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below